semaglutide restrictions A GLP-1 medication you swallow — no needle, no food — just had its first head-to-head trial results published. Orforglipron (Foundayo, Eli Lilly) was FDA-approved April 2026. In July 2026, the Semaglutide Dosing - Doctor's Advice

16 Finally, compared to other GLP-1 receptor agonists like dulaglutide, semaglutide is generally more potent, longer-acting, and often leads to greater HbA1c reductions and weight loss

Participants in the study who received glp-1 in conjunction with lifestyle intervention experienced an average weight loss of around 15% of their body weight within one year

In the phase 2 dose-escalation study (Jastreboff et al., NEJM, 2023), gastrointestinal adverse events were reported in a substantial proportion of participants, with incidence increasing at higher doses

Visceral hypersensitivity in IBS means that normal amounts of gas feel more painful and uncomfortable

Fibrotic encapsulation is the dominant source of continuous glucose monitor delays